Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678183 | 0.81 | ALDH1A1 (0.47) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL3682780 | 0.81 | MAPT (0.44) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL28399803 | 0.78 | GAA (0.50) | MAPTGAACNR1CNR2ALDH1A1 | |
| SCHEMBL48235 | 0.78 | MAPT (0.52) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL3682692 | 0.78 | MAPT (0.41) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL13445698 | 0.78 | RAB9A (0.38) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL13170447 | 0.77 | CNR1 (0.41) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL1252299 | 0.75 | GAA (0.50) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL12290954 | 0.75 | MAPT (0.52) | MAPTHTTSMN1; SMN2GAACNR1 | |
| SCHEMBL14126382 | 0.75 | GAA (0.43) | MAPTHTTSMN1; SMN2GAACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312944-B1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2312944-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010009243-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009243-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | MAPT 1284/4885HTT 480/4885SMN1; SMN2 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.